Press releases

Study seeks to confirm the safety and efficacy of systems in routine clinical practice

Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year

Study highlights importance of antiplatelet therapy compliance

Trial results report no new stent thrombosis after two years in high-risk patient population

Group supports call for limiting greenhouse gas emissions

Company anticipates broad range of clinical results on endoscopic technologies

Single-operator system allows unprecedented visual access to bile duct

Company to release broad range of clinical data on leading drug-eluting stent portfolio

More than 23,000 patients now enrolled in TAXUS OLYMPIA registry

New data provide support for minimally invasive treatment of atrial fibrillation (AF)

Data represents the industry's largest experience with wireless remote monitoring of implantable cardiac devices for one year

Reimbursement granted by National Health Insurance System

RENAISSANCE trial demonstrates durable results for Company's Express® SD Renal Stent in treating hypertensive patients with severe renal artery stenosis

Sam Leno will join the Company as Chief Financial Officer (CFO) and Executive Vice President of Finance and Information Systems

SYNTAX is the first trial to compare the results of drug-eluting stents with those of cardiac surgery in the most complex patient subsets

A live webcast and replay of the May 2 conference session will be available

"I am pleased we came in at the upper end of our ranges for sales and EPS for the quarter," said Jim Tobin, President and Chief Executive Officer

Product provides enhanced control for accessing desired vessel location

A live webcast and replay of the April 23 conference call will be available.

Company has resolved deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation

Company plans to launch the product after reimbursement approval is granted

Trial is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms

BTK CHILL study demonstrates high rate of limb protection at one year

TAXUS® Express2™ paclitaxel-eluting coronary stent system met its primary endpoint in the treatment of in-stent restenosis